ADMA Biologics (NASDAQ:ADMA) Trading 7.6% Higher – What’s Next?

ADMA Biologics Inc (NASDAQ:ADMA) was up 7.6% during trading on Monday . The stock traded as high as $10.56 and last traded at $10.4420. Approximately 1,054,549 shares changed hands during trading, a decline of 78% from the average daily volume of 4,784,270 shares. The stock had previously closed at $9.70.

Analyst Ratings Changes

Several equities research analysts have recently commented on ADMA shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Mizuho reduced their price target on shares of ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating for the company in a research report on Monday. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $28.00.

ADMA Biologics Trading Up 1.1%

The stock has a 50 day moving average of $13.78 and a 200-day moving average of $15.89. The company has a market capitalization of $2.50 billion, a P/E ratio of 17.48 and a beta of 0.82. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.20. The company had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm’s revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.46 EPS. On average, research analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Insider Buying and Selling

In related news, Director Steve Elms acquired 7,000 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was bought at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the purchase, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. The trade was a 0.34% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the transaction, the chief operating officer owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. This trade represents a 2.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. State Street Corp grew its stake in shares of ADMA Biologics by 0.3% during the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after acquiring an additional 35,614 shares during the period. Sachem Head Capital Management LP boosted its stake in ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after purchasing an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP boosted its stake in ADMA Biologics by 36.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock worth $127,551,000 after purchasing an additional 1,886,105 shares during the period. Capital Research Global Investors raised its position in shares of ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after buying an additional 3,383,559 shares during the last quarter. Finally, Nuveen LLC raised its position in shares of ADMA Biologics by 3.5% during the fourth quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock valued at $108,097,000 after buying an additional 202,245 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.